Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 17Dermatologic 8Gynecologic 7Genitourinary 7Gastrointestinal 7Thoracic 6Other solid neoplasm 2Breast 1

Conditions

Solid Tumors 11Mesothelioma, Malignant 8Solid Tumor 6Advanced Solid Tumor 6Mesothelioma 3Melanoma 3Carcinoma, Renal Cell 3Carcinoma, Non-Small-Cell Lung 3Advanced Solid Tumors 3Treatment-Refractory Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Merkel Cell 2Wilms Tumor 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thoracic Neoplasms 1Stomach Neoplasms 1Solid Tumour 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Select Advanced Solid Tumors 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Locally Advanced or Metastatic Solid Tumors 1Locally Advanced Solid Tumors 1Locally Advanced Solid Tumor 1Kidney Neoplasms 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1Gastrointestinal Neoplasms 1

Interventions

pembrolizumab 9Nivolumab 3tislelizumab 2spartalizumab 2atezolizumab 2SS1(dsFv)PE38 2Ipilimumab 2talazoparib 1obinutuzumab 1naptumomab estafenatox 1milademetan 1epacadostat 1entinostat 1durvalumab 1Tablets 1Polymerase Chain Reaction 1Paclitaxel 1Microarray Analysis 1Levoleucovorin 1Leucovorin 1Interleukin-2 1Immunoenzyme Techniques 1Gene Expression Profiling 1Flow Cytometry 1Fentanyl 1Erlotinib Hydrochloride 1Docetaxel 1Combined Modality Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Squamous Cell Carcinoma of Head and Neck × atezolizumab × Other solid neoplasm × Clear all
NCT06444815 2026-04-07

STEALTH-001

KaliVir Immunotherapeutics

Phase 1 Recruiting
60 enrolled
DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Mesothelioma

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

Rain Oncology Inc

Phase 1/2 Withdrawn
DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡